MAPK3 and prostate cancer: The antiapoptotic prosurvival pathway and the SphK1/S1P pathway, which is a product of the ERK1/2 pathway, were both blocked by RES, leading to the suppression of prostate cancer (PCa) both in vitro and in vivo [47].